Vascular Solutions Announces the Launch of the PolarCath Peripheral Dilatation System

MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. recently announced the launch of the PolarCath peripheral dilatation system for use in dilating stenoses in the peripheral vasculature (iliac, femoral, popliteal, infrapopliteal, renal, and subclavian arteries) and for the treatment of obstructive lesions of polytetrafluoroethylene (PTFE) access grafts or arteriovenous dialysis fistulae. The PolarCath system is also indicated for post-deployment stent expansion of self-expanding peripheral vascular stents.

Abiomed Impella 2.5 Receives FDA Approval for Elective and Urgent High Risk PCI Procedures

Impella 2.5 is the Only FDA-Approved Percutaneous Hemodynamic Support Device Determined to be Safe and Effective for the High Risk PCI Indication
 

CathPCI Registry: Short Hospital Stays After Angioplasty Following Heart Attack Often Sufficient

Older patients with no in-hospital complications are good candidates
 
WASHINGTON (March 23, 2015)—Patients 65 or older discharged from the hospital as early as 48 hours after angioplasty following a major heart attack  have similar outcomes as those who stay four to five days, provided there are no in-hospital complications. This finding was published today in the Journal of the American College of Cardiology.
 

83rd Annual Congress of the European Atherosclerosis Society (EAS) Clinical Latebreaker: Statins Reduce Hospital Admission for Heart Failure

  • Clinically important 10 percent reduction in hospital admission for heart failure
  • Benefit likely to be greater in the long-term

March 23, 2015 — Heart failure is costly, mainly due to frequent and prolonged admissions to hospital, and the condition is associated with a poor prognosis. Researchers from the University of Glasgow showed in a collaborative meta-analysis of 17 statin trials including over 100,000 patients, that statin treatment led to a 10 percent significant reduction in hospital admission for heart failure over an average of 4 years treatment.

CardioKinetix Announces Excellent Results of Chinese Trial Evaluating Parachute Heart Failure Device

MENLO PARK, Calif. & BEIJING--(BUSINESS WIRE)--CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced three-month clinical and echocardiographic results of PARACHUTE China, a study of 31 Chinese patients treated consecutively with the company’s Parachute® Ventricular Partitioning Device.

Protégé GPS Self-Expanding Peripheral Stent System Receives FDA Approval for Use in Treating Iliac Artery Stenosis

DUBLIN ––March 18, 2015 –– Medtronic plc announced that its Protégé GPS self-expanding peripheral stent system has received approval from the U.S. Food and Drug Administration (FDA) for the treatment of stenotic lesions of the common and external iliac arteries.
 

Culprit Plus Non-Culprit Artery Angioplasty w/ FFR Use Safe for STEMI

Proactive follow-up procedure may reduce future angioplasty or bypass
 

SAN DIEGO (Mar 16, 2015) -

Routine Manual Thrombectomy During Angioplasty Associated With No Benefit and Increased Stroke Rate

SAN DIEGO (Mar 16, 2015) -

A technique used to clear blood clots from arteries to the heart in about 20 percent of patients undergoing angioplasty appears to increase the risk of stroke without providing the intended benefit, according to a study presented at the American College of Cardiology’s 64th Annual Scientific Session.

Patients 80 Years and Older Would Benefit from Aggressive Treatment

Study suggests older patients may be denied invasive treatments unnecessarily
 
SAN DIEGO (Mar 16, 2015) -

Patients over age 80 with acute coronary syndromes would likely benefit from more invasive tests and therapies that may otherwise be denied them due to their age, according to research presented at the American College of Cardiology’s 64th Annual Scientific Session in San Diego.


Back to top